$107 Million is the total value of Copernicus Capital Management, LLC's 16 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 46.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | Buy | GILEAD SCIENCES INC | $12,544,000 | +25.5% | 197,916 | +33.8% | 11.67% | +31.3% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $10,987,000 | -15.4% | 64,849 | -8.5% | 10.22% | -11.6% |
| BMY | Sell | BRISTOL MYERS SQUIBB CO | $10,037,000 | -8.9% | 197,937 | -18.5% | 9.34% | -4.7% |
| ABBV | New | ABBVIE INC | $9,995,000 | – | 132,000 | +100.0% | 9.30% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $9,166,000 | – | 136,000 | +100.0% | 8.53% | – |
| IQV | Buy | IQVIA HLDGS INC | $8,662,000 | +107.2% | 57,986 | +123.1% | 8.06% | +116.7% |
| TMO | Sell | THERMO FISHER SCIENTIFIC INC | $8,440,000 | -20.1% | 28,976 | -19.5% | 7.85% | -16.4% |
| HUM | Sell | HUMANA INC | $7,926,000 | -27.1% | 31,000 | -24.4% | 7.37% | -23.8% |
| CNC | New | CENTENE CORP DEL | $6,359,000 | – | 147,000 | +100.0% | 5.92% | – |
| MRK | Sell | MERCK & CO INC | $6,229,000 | -47.3% | 74,000 | -47.5% | 5.80% | -44.9% |
| CDNA | Buy | CAREDX INC | $4,180,000 | -10.5% | 184,855 | +42.4% | 3.89% | -6.4% |
| ZTS | Sell | ZOETIS INCcl a | $3,784,000 | -33.8% | 30,375 | -39.7% | 3.52% | -30.8% |
| ILMN | Sell | ILLUMINA INC | $2,834,000 | -71.8% | 9,316 | -65.9% | 2.64% | -70.5% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $2,687,000 | -33.8% | 335,000 | +3.1% | 2.50% | -30.7% |
| SIEN | Buy | SIENTRA INC | $2,495,000 | +12.5% | 385,000 | +6.9% | 2.32% | +17.6% |
| FATE | New | FATE THERAPEUTICS INC | $1,165,000 | – | 75,000 | +100.0% | 1.08% | – |
| SYK | Exit | STRYKER CORP | $0 | – | -18,597 | -100.0% | -3.40% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -30,000 | -100.0% | -4.06% | – |
| ISRG | Exit | INTUITIVE SURGICAL INC | $0 | – | -11,201 | -100.0% | -5.23% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC | 15 | Q2 2021 | 28.6% |
| THERMO FISHER SCIENTIFIC INC | 10 | Q3 2021 | 13.8% |
| ZOETIS INC | 10 | Q1 2020 | 13.0% |
| FATE THERAPEUTICS INC | 9 | Q3 2021 | 13.7% |
| ILLUMINA INC | 9 | Q4 2019 | 11.8% |
| BIOMARIN PHARMACEUTICAL INC | 8 | Q3 2021 | 14.7% |
| BRISTOL-MYERS SQUIBB CO | 8 | Q4 2020 | 12.2% |
| INTUITIVE SURGICAL INC | 7 | Q2 2019 | 11.8% |
| STRYKER CORP | 7 | Q2 2019 | 11.6% |
| IQVIA HLDGS INC | 7 | Q4 2020 | 8.2% |
View Copernicus Capital Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-16 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
View Copernicus Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.